Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Klin Med (Mosk) ; 88(5): 52-5, 2010.
Article de Russe | MEDLINE | ID: mdl-21089460

RÉSUMÉ

Emergency abdominal surgery for peritonitis is a topical problem awaiting solution. Disturbed immune status of patients with peritonitis dictates the necessity to supplement postoperative intensive therapy by medical preparation normalizing immune functions. We have studied 36 patients with generalized peritonitis of different etiology of whom 20 (controls) were treated by traditional methods and 16 received standard therapy plus polyoxidomium. The frequency of abdominal and other complications in the latter group decreased to 19.2% and lethality to 13.8% while duration of the hospital stay was reduced by 3.6 patient days.


Sujet(s)
Facteurs immunologiques/usage thérapeutique , Péritonite/traitement médicamenteux , Pipérazines/usage thérapeutique , Polymères/usage thérapeutique , Adolescent , Adulte , Sujet âgé , Association thérapeutique , Femelle , Humains , Mâle , Adulte d'âge moyen , Péritonite/mortalité , Péritonite/chirurgie , Soins postopératoires , Résultat thérapeutique , Jeune adulte
2.
Ter Arkh ; 75(4): 58-60, 2003.
Article de Russe | MEDLINE | ID: mdl-12793141

RÉSUMÉ

AIM: To study efficacy of primalan (mequitasine) in the treatment of allergic rhinoconjunctivitis and chronic recurrent urticaria. MATERIAL AND METHODS: The study included 140 patients. Of them, 60 patients had allergic rhinitis, 80 patients had chronic recurrent urticaria. All the patients received primalan (mequitasin) in a dose 10 mg/day (5 mg twice daily or a single dose 10 mg). The disease symptoms and side effects of primalan were assessed for 28 days of the treatment. RESULTS: Primalan (mequitasin) proved to be highly effective against allergic rhinitis (good and very good response--76%, satisfactory--20%) and chronic recurrent urticaria (the response in 90% patients). Good primalan tolerance was reported. Side effects were moderate and did not require the drug withdrawal (sleepiness in 6.6%, dryness of the mucosa in 5%). CONCLUSION: Primalan (mequitasin) can be recommended for wide application in therapy of allergic rhinitis and chronic recurrent urticaria.


Sujet(s)
Antihistaminiques des récepteurs H1/usage thérapeutique , Hypersensibilité/traitement médicamenteux , Phénothiazines/usage thérapeutique , Adolescent , Adulte , Sujet âgé , Enfant , Femelle , Antihistaminiques des récepteurs H1/effets indésirables , Humains , Hypersensibilité/classification , Mâle , Adulte d'âge moyen , Phénothiazines/effets indésirables , Résultat thérapeutique
3.
Ter Arkh ; 70(5): 14-20, 1998.
Article de Russe | MEDLINE | ID: mdl-9644735

RÉSUMÉ

AIM: Clinicoimmunological study of adult patients with prevailing defect of humoral immunity, development of diagnostic criteria and treatment of this disease. MATERIALS AND METHODS: Clinical, immunological and microbiological examinations were made in 68 patients with defects of antibody formation. RESULTS: Total variable immunodeficiency (TVID), selective deficiency of IgA, congenital agammaglobulinemia, hyper-IgM-syndrome were detected in 74, 13, 10 and 3% of patients, respectively. TVID was frequently associated with respiratory, chronic ENT and gastrointestinal diseases, low CD4+ and high CD8+ levels. The response was achieved with combined therapy: antibacterial treatment + immunocorrection + differentiated replacement with plasma or immunoglobulins. CONCLUSION: In choice of immunotherapy of TVID patients it is necessary to consider parameters of immunogram. Intravenous administration of immunoglobulin preparations provided the highest effect in good safety.


Sujet(s)
Déficit immunitaire commun variable/thérapie , Immunoglobulines par voie veineuse/usage thérapeutique , Immunothérapie , Adolescent , Adulte , Production d'anticorps/immunologie , Lymphocytes B/immunologie , Transfusion de composants du sang , Rapport CD4-CD8 , Déficit immunitaire commun variable/sang , Déficit immunitaire commun variable/immunologie , Études de suivi , Humains , Immunoglobuline G/sang , Adulte d'âge moyen , Plasma sanguin , Induction de rémission , Lymphocytes T/immunologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE